Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer.

Similar associations were seen when including only pathogenic mutations, albeit patients with pathogenetic TP53 mutations had decreased PFS but this did not reach statistical significance ( Supplementary Figure S2 A-C, available at https://doi.org/10.1016/j.esmoop.2025.105506 ).

also in 111,027 other papers